Mirum Pharmaceuticals, Inc. (MIRM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6047491013
Mirum Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 521.31 m USD |
| Operating income | -22.14 m USD |
| EBIT | -19.77 m USD |
| Net income | -23.36 m USD |
| Diluted EPS – continuing operations | -0.47 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
More stocks
- Azimut Holding SpA (AZM.MI)
- Chailease Holding Co Ltd (5871.TW)
- AL Sydbank A/S (ALSYDB.CO)
- Shan Dong Sun Paper Industry Joint Stock Co Ltd (002078.SZ)
- Canon Marketing Japan Inc (8060.T)
- Waystar Holding Corp. (WAY)
- British Land Company PLC (BLND.L)
- Sichuan Huafeng Technology Co. Ltd. A (688629.SS)
- Nanjing Tanker Corp (601975.SS)
- Loongson Technology Corp. Ltd. A (688047.SS)
- MERIT MEDICAL SYSTEMS INC (MMSI)
- Dutch Bros Inc. (BROS)
Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.